A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects With Locally Advanced or Metastatic Solid Tumors
-
Enrollment
This study is not currently enrolling. -
Research Area
Cancer Research -
Principal Investigator
-
Sponsor
Daiichi Sankyo, Inc.
The purpose of this study is to learn more about an investigational drug called patritumab deruxtecan (also known as HER3-DXd or U3-1402), also referred to as “study drug” or “study treatment” throughout this informed consent form.